Low bone density in systemic sclerosis. a systematic review

Journal of Rheumatology

Volumn 40, Issue 11, 2013, Pages 1881-1890

  Omair, Mohammed A ^a   Pagnoux, Christian ^a   McDonald Blumer, Heather ^a   Johnson, Sindhu R ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

BONE DENSITY; FRACTURE REVIEW; OSTEOPENIA; OSTEOPOROSIS; SCLERODERMA; SYSTEMIC SCLEROSIS

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CENTROMERE ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PENICILLAMINE; PHOSPHORUS; SCL 70 ANTIBODY; VITAMIN D;

ADULT; AGE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE TURNOVER; CALCINOSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; EXERCISE; FAMILY HISTORY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MORTALITY; OSTEOPENIA; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; PROPENSITY SCORE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SMOKING; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; VITAMIN D DEFICIENCY;

BONE DENSITY; FRACTURE REVIEW; OSTEOPENIA; OSTEOPOROSIS; SCLERODERMA; SYSTEMIC SCLEROSIS;

BONE DENSITY; BONE DISEASES, METABOLIC; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84887484489     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130032     Document Type: Review

References (48)

1. Kucharz EJ, Grucka-Mamczar E, Mamczar A, Brzezinska-Wcislo L. Acute-phase proteins in patients with systemic sclerosis. Clin Rheumatol 2000;19:165-6.
2. Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis 1982;41:147-52.
3. Johnson SR, Gladman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006;33:1117-22.
4. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011;38:289-96.
5. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87.
6. Loucks J, Pope JE. Osteoporosis in scleroderma. Semin Arthritis Rheum 2005;34:678-82.
7. Antonelli A, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 2007;156:431-7.
8. Kucharz EJ. Thyroid disorders in patients with progressive systemic sclerosis: a review. Clin Rheumatol 1993;12:159-61.
9. Brewer L, Williams D, Moore A. Current and future treatment options in osteoporosis. Eur J Clin Pharmacol 2011;67:321-31.
10. Qaseem A, Snow V, Shekelle P, Hopkins R Jr., Forciea MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15.
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
12. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
13. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii36-9.
14. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther 2012;34:521-36.
15. Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009;36:1924-9.
16. Rios Fernandez R, Fernandez Roldan C, Callejas Rubio JL, Ortego Centeno N. Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J Rheumatol 2010;37:1355; author reply 1356.
17. Hayden JA, Cote P, Steenstra IA, Bombardier C. Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies. J Clin Epidemiol 2008;61:552-60.
18. La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. Clin Rheumatol 1991;10:18-22.
19. La Montagna G, Baruffo A, Abbadessa S, Maja L, Tirri R. Evidence for bone resorption in systemic sclerosis. J Rheumatol 1995;22:797-9.
20. Frediani B, Baldi F, Falsetti P, Acciai C, Filippou G, Spreafico A, et al. Bone mineral density in patients with systemic sclerosis. Ann Rheum Dis 2004;63:326-7.
21. Frediani B, Baldi F, Falsetti P, Acciai C, Filippou G, Spreafico A, et al. Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin Exp Rheumatol 2004;22:313-8.
22. Neumann K, Wallace DJ, Metzger AL. Osteoporosis-less than expected in patients with scleroderma? J Rheumatol 2000;27:1822-3.
23. D'Amore M, Minenna G, Fanelli M, D'Amore S, Favoino B. Bone density and HLA antigens in patients with progressive systemic sclerosis. Minerva Med 2005;96:61-2.
24. Carbone L, Tylavsky F, Wan J, McKown K, Cheng S. Bone mineral density in scleroderma. Rheumatology 1999;38:371-2.
25. Di Munno O, Mazzantini M, Massei P, Ferdeghini M, Pitaro N, Latorraca A, et al. Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis. Clin Rheumatol 1995;14:407-12.
26. da Silva HC, Szejnfeld VL, Assis LS, Sato EI. Estudo da densidade óssea em esclerodermia sistêmica [Portuguese]. Study of bone density in systemic scleroderma. Rev Assoc Med Bras 1997;43:40-6.
27. Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, et al. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis. J Rheumatol 2008;35:2206-13.
28. Sampaio-Barros PD, Costa-Paiva L, Filardi S, Sachetto Z, Samara AM, Marques-Neto JF. Prognostic factors of low bone mineral density in systemic sclerosis. Clin Exp Rheumatol 2005;23:180-4.
29. Souza RB, Borges CT, Takayama L, Aldrighi JM, Pereira RM. Systemic sclerosis and bone loss: the role of the disease and body composition. Scand J Rheumatol 2006;35:384-7.
30. Yuen SY, Rochwerg B, Ouimet J, Pope JE. Patients with scleroderma may have increased risk of osteoporosis. A comparison to rheumatoid arthritis and noninflammatory musculoskeletal conditions. J Rheumatol 2008;35:1073-8.
31. Zurek M. The evaluation of bone mineral density and risk factors of osteoporosis in patients with diffuse connective tissue diseases. Osteologicky Bulletin 2003;8:125-30.
32. Serup J, Hagdrup H, Tvedegaard E. Bone mineral content in systemic sclerosis measured by photonabsorptiometry. Acta Derm Venereol 1983;63:235-7.
33. Sampaio-Barros PD, Magalhães EP, Sachetto Z, Samara AM, Neto JF. Bone mineral density in systemic sclerosis. Rev Bras Rheumatol 2000;40:153-8.
34. Alexandersson BT, Geirsson AJ, Olafsson I, Franzson L, Sigurdsson G, Gudbjornsson B. Beiñéttni og umsetning í herslismein [Icelandic]. Bone mineral density and bone turnover in systemic sclerosis. Laeknabladid 2007;93:535-41.
35. Hagdrup H, Serup J, Tvedegaard E. Does long-term treatment with D-penicillamine alter calcium and phosphorus metabolism in patients with systemic sclerosis? Acta Derm Venereol 1983; 63:447-9.
36. Allanore Y, Borderie D, Lemarechal H, Cherruau B, Ekindjian OG, Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003;30:68-73.
37. Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344:23-7.
38. Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 2012;64:2-8.
39. Zofkova I. Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism. Physiological Res 2003;52:657-79.
40. Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008;35:2363-71.
41. Weiss RJ, Wick MC, Ackermann PW, Montgomery SM. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases-a case-control study with 53,108 patients with fracture. J Rheumatol 2010;37:2247-50.
42. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone 2009;44:734-43.
43. Lo JC, Pressman AR, Chandra M, Ettinger B. Fracture risk tool validation in an integrated healthcare delivery system. Am J Manag Care 2011;17:188-94.
44. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73.
45. Hawker GA, Gignac MA. How meaningful is our evaluation of meaningful change in osteoarthritis? J Rheumatol 2006;33:639-41.
46. Johnson SR, Swiston JR, Granton JT. Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension. J Rheumatol 2008;35:1584-90.
47. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998;52:289-303.
48. Omair MA, McDonald-Blumer H, Johnson SR. Bone disease in systemic sclerosis: outcomes and associations. Clin Exp Rheumatol 2014. In press.